Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: former_pgs who wrote (17405)	8/29/2005 3:32:16 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 52153

former_pgs, Not sure if you invited me to share other developments (other than cytk/myosin) in the investible CV space; but, so, well anyway...Cardiome (which has an advanced iv anti-atrial fib program) acquires a pre-clincical CV pipe. (On sensible and, I think, favorable terms.) Cardiome Announces Letter Of Intent To Acquire Artesian Therapeutics Monday August 29, 1:57 pm ET NASDAQ: CRME TSX: COM VANCOUVER, Aug. 29 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) announced today that it has executed a letter of intent ("LOI") to acquire Artesian Therapeutics, Inc., a privately held U.S. biopharmaceutical company. Headquartered in Gaithersburg, Maryland, Artesian was founded in March of 2002 to discover and develop bi-functional small- molecule drugs for the treatment of cardiovascular disease. Artesian currently has two advanced small molecule discovery programs in the area of congestive heart failure ("CHF"). Artesian's lead program is focused on a series of dual-pharmacophore compounds designed to simultaneously inhibit the cardiac phosphodiesterase enzyme (PDE3), causing inotropic effects, while inhibiting the L-Type Calcium channel to protect against calcium overload. Artesian's second program focuses on a novel strategy to attenuate the deleterious effects of the excessive neurohormonal activation which occurs in congestive heart failure (CHF). Under the terms of the proposed acquisition, payments to Artesian shareholders are contingent on the achievement of certain pre-defined clinical milestones. The milestone payments will equal, in the aggregate, US$32 million for each of the first two drug candidates from the Artesian programs that reach NDA approval. The first such milestone is due upon initiation of the clinical development of an Artesian drug candidate. Concurrent with closing of the proposed acquisition, Oxford Bioscience Partners, Artesian's largest shareholder, will invest US$7.5 million into Cardiome at a price of approximately US$7.24 per share, a 5% premium over the five day average closing price of the common shares of Cardiome on the NASDAQ Stock Market prior to the execution of the LOI.